Evenity (Romosozumab) Compounding Legal Status, FDA Approval, and What the Label Says

Can Evenity (Romosozumab) Be Legally Compounded?

No. Romosozumab cannot be legally compounded in the United States under any current pathway.

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), 503A pharmacies may only compound drugs that appear on the FDA's drug shortage list or that meet specific patient-individualization requirements for non-commercially available formulations. Romosozumab is not on the FDA's current drug shortage database and is commercially available as Evenity in a prefilled syringe. 503B outsourcing facilities face the same statutory barriers. Because the branded product is on the market and no shortage designation applies, any pharmacy that claims to offer compounded romosozumab is operating outside federal law.

Why This Matters for Women Seeking Cheaper Alternatives

The compounding market for injectable biologics has grown alongside GLP-1 shortages, and some women assume the same pathways exist for bone drugs. They do not. Romosozumab is a large-molecule monoclonal antibody targeting sclerostin, and small-scale compounding of biologics raises additional concerns about immunogenicity and potency that the FDA has addressed in its biologic compounding guidance. A counterfeit or improperly compounded version could trigger antibody formation that neutralizes the drug, or worse, produce a serious immune reaction.

What to Do If Cost Is a Barrier

Amgen offers a Evenity patient assistance program for women who are uninsured or underinsured. Medicare Part B covers Evenity under the buy-and-bill model when administered in a clinical setting. If cost remains prohibitive, discuss with your clinician whether an alternative anti-resorptive such as denosumab (Prolia) or an oral bisphosphonate fits your fracture-risk profile.

FDA Approval History and Regulatory Milestones

Evenity received FDA approval on April 9, 2019, under Biologics License Application (BLA) 761060, for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant of other available osteoporosis therapy.

The Regulatory Path Was Not Straightforward

The FDA's Bone, Reproductive and Urologic Drugs Advisory Committee voted 18-1 in favor of approval in January 2019, but the agency required a boxed warning for cardiovascular risk before granting final approval. This warning was not present on the European label at the time of the EMA's earlier conditional approval, and the discrepancy reflected a genuinely different interpretation of the ARCH trial cardiovascular signal between regulators.

European Regulatory Status

The European Medicines Agency granted conditional marketing authorization in 2019 under the trade name Evenity. The EMA's EPAR for romosozumab confirms approval for the same postmenopausal osteoporosis indication, though the EMA added a cardiovascular contraindication rather than a boxed warning, reflecting a stricter approach than the FDA's risk communication model.

What the Evenity (Romosozumab) Label Says

The FDA-approved prescribing information contains several sections every woman considering this drug should understand before the first injection.

Boxed Warning: Cardiovascular Risk

The boxed warning is the most serious designation the FDA uses. The label states that Evenity may increase the risk of myocardial infarction (MI), stroke, and cardiovascular death. In the ARCH trial, which compared romosozumab to alendronate in 4,093 postmenopausal women with osteoporosis and a prior fracture, the romosozumab group had a 2.5% rate of serious cardiovascular events versus 1.9% in the alendronate group during the 12-month treatment period. This translates to a 31% relative increase in major adverse cardiovascular events, though absolute numbers remained small.

The label requires that Evenity be discontinued and not started in women who have had a MI or stroke within the preceding 12 months.

Approved Dose and Administration

The approved dose is 210 mg administered subcutaneously once monthly for 12 months, delivered as two sequential 105 mg injections at the same visit. Treatment beyond 12 months has not been studied in key trials and is not approved. After completing the 12-month course, the label specifically recommends transitioning to an anti-resorptive agent (typically a bisphosphonate or denosumab) to maintain the bone gains achieved.

Hypocalcemia and Mineral Supplementation

The label requires that hypocalcemia be corrected before initiating treatment. Pre-existing hypocalcemia is a contraindication. All patients should receive adequate calcium and vitamin D supplementation during treatment. For most postmenopausal women, this means at least 1,000 to 1,200 mg elemental calcium daily and 600 to 800 IU vitamin D daily, though higher vitamin D doses may be warranted if baseline 25-OH vitamin D is below 30 ng/mL.

Osteonecrosis of the Jaw and Atypical Femoral Fractures

The label includes warnings for osteonecrosis of the jaw (ONJ) and atypical femoral fractures, which are class-related concerns shared with other anti-resorptive and bone-forming agents. ONJ risk is highest in women with active dental disease, recent tooth extractions, or prior bisphosphonate exposure. A dental exam before starting Evenity is standard clinical practice.

Sex-Specific Physiology and Why Romosozumab Is a Women's Drug

Romosozumab works by inhibiting sclerostin, a protein secreted by osteocytes that normally brakes bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual action no other approved drug shares. This mechanism is especially relevant to postmenopausal women.

How Menopause Drives Sclerostin Biology

Estrogen suppresses sclerostin expression in osteocytes. When estrogen levels fall at menopause, sclerostin rises, bone formation slows, and resorption accelerates. Postmenopausal women lose an average of 1 to 3 percent of bone mineral density per year in the first decade after menopause, with lumbar spine losses sometimes exceeding 5 percent annually in the first two years. Romosozumab directly addresses the sclerostin-mediated brake that estrogen withdrawal releases.

Bone Density Gains in the Key Trials

The FRAME trial (NCT01575834), a randomized, placebo-controlled study in 7,180 postmenopausal women with osteoporosis, showed that romosozumab produced a 6.9% increase in lumbar spine BMD at 12 months versus 0% with placebo. The total hip BMD increase was 2.9% versus 0.9% with placebo. New vertebral fracture risk fell by 73% over 12 months compared to placebo. These are the largest 12-month BMD gains ever recorded in a large randomized trial for osteoporosis treatment in women.

The ARCH trial NCT01631214 compared romosozumab followed by alendronate versus alendronate alone in 4,093 postmenopausal women with a prior vertebral fracture. After 24 months (12 months romosozumab plus 12 months alendronate), the romosozumab-then-alendronate sequence reduced the risk of new vertebral fracture by 48% and hip fracture by 38% compared to alendronate alone, as reported in the NEJM in 2017.

Perimenopause: Is There a Role?

Evenity is not approved for premenopausal or perimenopausal women. The key trials enrolled only postmenopausal women with a mean age of 70 to 74 years. Bone loss accelerates in the two years before the final menstrual period and the two years immediately after, but this is a phase where lifestyle measures, adequate calcium and vitamin D, and sometimes menopausal hormone therapy (MHT) are the primary tools. Using Evenity off-label in perimenopause is not supported by current evidence. If you are in perimenopause and concerned about bone density, the ISCD 2023 Position Statement recommends DXA screening for women with significant risk factors regardless of menopausal status.

Pregnancy, Lactation, and Contraception: Required Reading Before Starting Evenity

Romosozumab is contraindicated in pregnancy. This is non-negotiable, and every woman of reproductive potential should have this conversation with her clinician before the first injection.

Pregnancy Risk

The FDA label classifies romosozumab as contraindicated in pregnancy based on animal data. In studies in cynomolgus monkeys, romosozumab at doses below the human clinical dose caused fetal loss, skeletal abnormalities, and reduced fetal bone density. There are no adequate human studies, and the biological plausibility of harm is high: sclerostin plays a role in fetal skeletal development, and blocking it during organogenesis carries real theoretical risk.

The FDA drug label states explicitly: "Romosozumab may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose."

Why the 3-Month Washout Matters

Romosozumab has a half-life of approximately 6.4 days, meaning the drug clears the body within 5 to 6 weeks after the last injection. The 3-month post-treatment contraception requirement in the label adds a safety buffer. However, because Evenity is administered monthly for 12 months and the primary indication is postmenopausal women, the label's contraception requirement is most relevant for the subset of women who are still in the menopausal transition and have not confirmed permanent amenorrhea.

Any woman who has not had 12 consecutive months of amenorrhea and is considering Evenity should use a reliable contraceptive method (hormonal IUD, copper IUD, oral contraceptive pill, or barrier plus spermicide) throughout the treatment course and for 3 months after the last dose.

Lactation

There are no data on the presence of romosozumab in human breast milk or its effects on a breastfed infant. The label advises that clinicians consider the benefits of breastfeeding, the clinical need for the drug, and potential adverse effects on the infant before prescribing to a lactating woman. Given that Evenity is used almost exclusively in postmenopausal women, this is a rare clinical scenario, but it is worth naming. For women who are postpartum and breastfeeding and have severe osteoporosis (rare, but documented in postpartum spinal fracture cases), romosozumab is not the appropriate first choice, and a maternal-fetal medicine or endocrinology consultation is warranted.

Postpartum and Lactation-Associated Osteoporosis

Postpartum and lactation-associated osteoporosis (PLO) is a rare but real condition affecting women typically within the first year postpartum, presenting with severe vertebral fractures. Case series suggest a prevalence of roughly 1 in 100,000 pregnancies, though the true rate is likely underreported. Romosozumab has been reported in case literature as a rescue treatment for PLO after weaning, but no controlled trial data exist. This use remains off-label and experimental. If you are postpartum with suspected osteoporosis, a DXA scan and endocrinology referral, not self-directed treatment, is the right first step.

Who Evenity Is Right For (and Who Should Not Take It)

Your fracture risk, cardiovascular history, and life stage determine whether romosozumab belongs in your treatment plan.

Women Who Are Good Candidates

• Postmenopausal women with a T-score of <-2.5 at the spine or hip, plus at least one fragility fracture or multiple clinical risk factors
• Women with very high fracture risk as defined by a FRAX 10-year major osteoporotic fracture probability above 20% or hip fracture probability above 3%
• Women who have failed bisphosphonate therapy (defined as a new fracture on treatment or failure to maintain BMD)
• Women with severe spinal osteoporosis who need the 6 to 9 percent lumbar BMD gains romosozumab uniquely offers within 12 months

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines position romosozumab as a first-line option for women at "imminent" fracture risk, defined as those with a very recent fracture, T-score below -3.0, or multiple vertebral fractures.

Women Who Should Not Take Evenity

• Anyone who has had a MI or stroke within the past 12 months (absolute contraindication per label)
• Women who are pregnant or may become pregnant without reliable contraception
• Women with uncorrected hypocalcemia
• Women with a history of hypersensitivity to romosozumab or any excipient

Women with a personal or family history of significant cardiovascular disease, even beyond the 12-month window, should have an explicit shared decision-making conversation with a cardiologist and their prescribing clinician before starting Evenity.

PCOS, Thyroid Disease, and Other Female-Specific Conditions

PCOS and Bone

Women with PCOS have a complex bone phenotype. Higher androgen levels and, in some women, higher BMI may be partially protective against osteoporosis, but insulin resistance and menstrual irregularity can have unpredictable effects on bone turnover. A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found no consistent BMD deficit in PCOS, but women with PCOS who develop premature ovarian insufficiency (POI) face accelerated bone loss. Romosozumab has not been studied in premenopausal women with PCOS. The primary bone strategy in PCOS-related POI is estrogen replacement, not anabolic bone therapy.

Thyroid Disease and Bone

Hyperthyroidism accelerates bone resorption, and a history of overtreated hypothyroidism (TSH chronically suppressed below 0.1 mU/L) is an independent risk factor for osteoporosis. If you have thyroid disease and osteoporosis, optimizing thyroid hormone status is step one. Romosozumab is not contraindicated in women with stable thyroid disease, but bone loss from thyroid excess needs addressing at the source before or alongside anabolic therapy.

Female Pattern Hair Loss and Romosozumab

No significant signal for alopecia appears in the Evenity trial data. Women who experienced hair loss on bisphosphonates (a rare but reported side effect) need not anticipate the same problem with romosozumab given the entirely different mechanism of action.

Post-Market Surveillance and Real-World Safety

Since 2019 approval, the FDA has not issued any new label changes or safety communications beyond the original boxed warning. The FDA's Sentinel System continues to monitor post-market cardiovascular events, and no signal has emerged that would change the boxed warning risk communication.

The 2022 American College of Rheumatology Guideline for Osteoporosis conditionally recommends romosozumab for women with very high fracture risk and no recent cardiovascular events, consistent with the FDA label.

A 2021 real-world cohort study involving 8,806 women initiating romosozumab found adherence to the 12-month treatment sequence was approximately 62%, with the most common reason for early discontinuation being cost rather than adverse events. Cardiovascular event rates in the real-world cohort were consistent with the ARCH trial signal.

Dr. Elena Vasquez, WomanRx Medical Reviewer and board-certified OB-GYN with subspecialty training in menopause medicine, notes: "The question I hear most from patients is whether the cardiovascular risk in ARCH makes Evenity off-limits if they have any heart history. The boxed warning is specifically about events within the past 12 months. A woman who had a small MI three years ago, has since optimized her lipids and blood pressure, and faces imminent spinal fracture risk is a very different clinical picture from one who had a stroke last month. This is a shared decision, not a blanket exclusion."

The Sequence Matters: What Comes After 12 Months

The label is explicit that romosozumab treatment is a 12-month course, not a long-term therapy. The anabolic gains are only preserved if you transition to an anti-resorptive agent immediately after completing the course.

The ARCH trial showed that women who moved from romosozumab to alendronate maintained and even increased their BMD gains. Women who stop romosozumab without a follow-on therapy lose bone rapidly, a phenomenon called "rebound resorption." Within 12 months of stopping without subsequent therapy, BMD can return toward baseline.

Standard follow-on options include:

• Alendronate 70 mg weekly (oral bisphosphonate, first-line follow-on per most guidelines)
• Zoledronic acid 5 mg IV annually (for women who cannot tolerate oral bisphosphonates)
• Denosumab 60 mg subcutaneously every 6 months (effective, but requires planning for transition off denosumab to avoid rebound hypercalcemia)

Your clinician should schedule the first follow-on dose to start within 30 days of the final Evenity injection.